Table 1. Comparison of demographics, HIV disease status, antiretroviral exposure, and comorbidities in HIV infected patients with and without sensory neuropathy (HIV-SN).
Age, CD4 current, duration of HIV infection, past and currently dideoynucleoside antiretroviral (d-drug) exposure, and past protease inhibitor (PI) exposure were significantly associated with HIV-SN.
| HIV-SN (n=71) | No HIV-SN (n=59) | p value | OR | 95% CI | |
|---|---|---|---|---|---|
| Demographic Characteristics | |||||
| Age (years old) | 49 | 43 | <0.001 | 1.06 | 1.05–1.15 |
| < 30 years old (% total) | 1 (1.4%) | 3 (5.1%) | Ref | ||
| 30–39 years old (% total) | 9 (12.7%) | 15 (25.4%) | 0.63 | 1.8 | 0.16–20.02 |
| 40–49 years old (% total) | 30 (42.2%) | 33 (55.9%) | 0.62 | 2.72 | 0.27–27.66 |
| 50–59 years old (% total) | 21 (29.6%) | 7 (11.9%) | 0.08 | 9.0 | 0.80–101.2 |
| ≥ 60 years old (% total) | 10 (14.1%) | 1 (1.7%) | 0.03 | 30.0 | 1.41–638.15 |
| Men (%) | 86 | 83 | 0.81 | ||
| HIV Disease Status | |||||
| Current CD4 (cells/mm3) | 599 | 431 | 0.04 | 1.01 | 1.00–1.01 |
| Nadir CD4 (cells/mm3) | 112 | 181 | 0.14 | ||
| Length of infection (mos) | 15 | 9 | < 0.001 | 1.11 | 1.07–1.25 |
| CSF VL (log 10) | 1.7 | 1.7 | 0.60 | ||
| Plasma VL (log 10) | 1.7 | 1.7 | 0.31 | ||
| Antiretroviral Characteristics | |||||
| D-drug exposure duration (mos) | 4.6 | 4.0 | 0.53 | ||
| D-drug Use | |||||
| Current | 19 | 11 | 0.04 | 2.65 | 1.04–6.63 |
| Past Use | 31 | 16 | < 0.01 | 1.71 | 1.30–6.68 |
| Never | 21 | 32 | - | - | |
| PIs Ever | |||||
| Current | 6 | 5 | 0.41 | ||
| Past Use | 45 | 25 | < 0.01 | 2.63 | 1.23–5.52 |
| Never | 20 | 29 | - | - | |
| Medical History | |||||
| % HCV | 11 | 15 | 0.6 | ||
| % Diabetes | 11 | 4 | 0.18 | ||
SN= sensory neuropathy
CSF= cerebral spinal fluid
PI- protease inhibitor
HCV= hepatitis C infection